Virologic Outcomes After LA ART Initiation with and without Viremia in Two Large U.S. Clinic Cohorts
Long-acting cabotegravir/rilpivirine supports virologic suppression among people with HIV (PWH) facing adherence challenges. In two large U.S. cohorts(n=1,070), 96% of viremic PWH achieved virologic suppression at a 4-week median. However, blips/failure were more frequent among PWH initiating with viremia, underscoring the need for careful monitoring and optimization of long-acting treatment.
Authors
- Jonathan A. Colasanti (ORCID: https://orcid.org/0000-0002-0536-9769)
- Matthew Spinelli (ORCID: https://orcid.org/0000-0002-1135-2787)
- Chesa Cox (ORCID: https://orcid.org/0000-0002-5918-2668)
- David V. Glidden (ORCID: https://orcid.org/0000-0001-5888-1419)
- Monica Gandhi (ORCID: https://orcid.org/0000-0002-7025-1994)
- Megan J. Heise (ORCID: https://orcid.org/0000-0001-6651-2381)
- Amalia Aldredge (ORCID: https://orcid.org/0000-0002-8044-4298)
- Larisa Niles-Carnes (ORCID: https://orcid.org/0000-0002-6817-4969)
- Eudiah Ochieng
- Lauren Frances Collins (ORCID: https://orcid.org/0000-0002-0170-5454)
- Nathanael Gistand
- Meredith H. Lora (ORCID: https://orcid.org/0009-0004-5999-6655)
- Jon Oskarsson
- Janet Grochowski
Institutions
- Grady Memorial Hospital (US)
- Emory University (US)
- University of California, San Francisco (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2026-06-29
- DOI
- https://doi.org/10.1093/cid/ciag392
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 0.00